Objectives:
1.Review the pathogenesis and immunogenicity of Classical Hodgkins Lymphoma
2. Discuss the current choices for salvage therapy in first relapse
3. Identify new strategies for salvage by incorporating immunotherapy and brentuximab vedotin
Session date:
02/27/2017 - 12:00pm to 1:00pm CST
Location:
UCMC
KCBD
Chicago, IL
60637
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Andrew Hantel & Anu Neerukonda